Impact of Preoperative Nesiritide on Renal Function after Mitral Valve Surgery
DOI:
https://doi.org/10.1532/HSF98.20091025Abstract
Nesiritide, a recombinant B-type natriuretic peptide used for the intravenous treatment of acute decompensated congestive heart failure. Concerns have been raised about the long-term use of nesiritide, but data is scarce regarding its use in acute congestive heart failure and during cardiac surgery. We conducted a retrospective data review to address the safety of nesiritide for pretreatment of patients undergoing mitral valve surgeryReferences
Cheng JW, Merl MY, Nguyen HM. 2005. Effect of nesiritide on renal function: a retrospective review. Curr Med Res Opin 21:1857-63.nDunavant S. 2002. Nesiritide vs nitroglycerin for decompensated congestive heart failure. JAMA 288:571-2; author reply 572-3.nSackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. 2005. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293:1900-5.nSalzberg SP, Filsoufi F, Anyanwu A, et al. 2005. High-risk mitral valve surgery: perioperative hemodynamic optimization with nesiritide (BNP). Ann Thorac Surg 80:502-6.nWang DJ, Dowling TC, Meadows D, et al. 2004. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 110:1620-5.n
